EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

From Algorithmic Prediction to Therapeutic Evidence: Artificial Intelligence in Drug Discovery, Translation, and Responsible Governance

Paola Carolina Rainer da Silva

Nexus Science Review · 2026

DOI: 10.66104/337xw232 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Nexus Science Review, 2026. Verfasst von Paola Carolina Rainer da Silva. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Artificial intelligence (AI) now supports target identification, molecular representation, virtual screening, structure prediction, de novo design, synthesis planning, drug repurposing, and prediction of absorption, distribution, metabolism, excretion, and toxicity (ADMET). These capabilities can expand the chemical and biological hypotheses evaluated before costly experiments, but computational novelty is not equivalent to a safe or effective medicine. This structured critical narrative review examines AI as part of an iterative discovery system linking data, algorithms, medicinal chemistry, experimental biology, pharmacology, manufacturing, and clinical development. The synthesis emphasizes evidence quality, applicability domain, prospective validation, reproducibility, and regulatory credibility. A detailed case analysis of halicin shows both the legitimate achievement and the boundary of AI-prioritized discovery: a graph neural network selected a structurally unusual antibacterial candidate, followed by laboratory and animal validation, yet the finding did not establish clinical efficacy or approval. Additional analysis covers AlphaFold-enabled structural hypothesis generation, AI-designed molecules, multi-objective optimization, ADMET modeling, automated laboratories, clinical-development support, and AI-enabled target discovery. The article proposes five author-defined evidence levels and an author-synthesized stage-gated governance framework. Major limitations include biased or noisy data, distribution shift, shortcut learning, inadequate uncertainty estimation, proprietary opacity, environmental cost, intellectual-property ambiguity, and unequal access to data and computation. AI can accelerate learning and improve prioritization, but therapeutic value requires progressively stronger experimental, translational, clinical, and, where applicable, regulatory evidence.

Zitieren

APA

Silva, P. C. R. D. (2026). From Algorithmic Prediction to Therapeutic Evidence: Artificial Intelligence in Drug Discovery, Translation, and Responsible Governance. Nexus Science Review. https://doi.org/10.66104/337xw232

Vancouver

Silva PCRD. From Algorithmic Prediction to Therapeutic Evidence: Artificial Intelligence in Drug Discovery, Translation, and Responsible Governance. Nexus Science Review. 2026. doi:10.66104/337xw232

BibTeX
@article{Silva2026,
  author = {Silva, Paola Carolina Rainer da},
  title = {From Algorithmic Prediction to Therapeutic Evidence: Artificial Intelligence in Drug Discovery, Translation, and Responsible Governance},
  journal = {Nexus Science Review},
  year = {2026},
  doi = {10.66104/337xw232}
}
Kostenlos starten →